· Brings nearly three decades of clinical, translational and biotechnology experience, strengthening ReBio’s leadership team as it prepares to advance RBP-01 into the clinic · RBP-01 targets primary uveal melanoma, the most common primary eye cancer in adults and an indication with no approved therapies Turku, Finland and Geneva, Switzerland, 22 July2026 – ReBioPharma (“ReBio” […]
€115 million out-licensing agreement Positive data from European confirmatory trial (PAES) Lund, Sweden, 22 July 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced its half year report for the period January-June 2026. Read more…
AP306 is a first-in-class pan phosphate transporter inhibitor in development as a monotherapy for hyperphosphatemia, a near-universal and serious complication in chronic kidney disease patients Study underway with first patient randomized in the global Phase 2b trial of AP306 conducted in partnership with Alebund in the US and China Study builds on positive Phase 2a […]
Continued momentum in Poolbeg’s global intellectual property strategy 21 July 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received a Notice of Allowance for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome (“CRS”) patent application from the Israeli Patent […]
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the innovative tissue-healing medical device company delivering high-performing solutions for better patient outcomes, today announces a trading update for the six months ended 30 June 2026. The Board is pleased to announce that it expects to report half year 2026 revenues of approximately £115.2 million (H1 2025: £110.8 […]
